Memantina Teva-Ratiopharm (Memantine Hydrochloride)

Memantine is used in the management of neurodegenerative conditions, primarily targeting cognitive decline associated with Alzheimer’s disease.

• Alzheimer’s disease (mild to moderate): helps improve cognition and daily functioning.
• Alzheimer’s disease (moderate to severe): supports modest benefits in memory and behavior.
• Dementia‑related cognitive impairment: may aid in slowing functional decline.

• Memantine acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor, binding to the receptor-associated ion channel. By reducing excessive calcium influx, it limits excitotoxic neuronal injury that contributes to the progression of Alzheimer’s disease, thereby helping preserve synaptic function and cognition.

Common Side Effects

• Dizziness: transient light‑headedness reported by some patients.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Fatigue: feeling of tiredness.
• Nausea: occasional upset stomach.
• Confusion: temporary mental clouding.

Serious or Rare Side Effects

• Seizures: rare but potentially severe neurological events.
• Allergic reactions: rash, itching, or swelling.
• Stevens‑Johnson syndrome: severe skin reaction.
• Hepatic dysfunction: abnormal liver enzymes.
• Cardiac arrhythmia: irregular heart rhythm.
• Psychosis: emergence of hallucinations or delusions.

Memantine requires careful consideration in several clinical situations.

• Renal impairment: dose may need adjustment.
• Hepatic impairment: monitor liver function.
• History of seizures: use with caution.
• Concomitant NMDA antagonists: avoid combined use.
• Pregnancy: risk unknown, prescribe only if essential.
• Store at room temperature: keep in original container, protect from moisture.

Memantine can interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase toxicity.
• Ketamine: combined NMDA blockade can cause severe CNS effects.
• Other NMDA antagonists: heightened risk of neuropsychiatric events.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines): may enhance sedation.
• Anticholinergic agents: could worsen cognitive side effects.
• Diuretics: may affect electrolyte balance.
• Antihypertensives: monitor blood pressure changes.
• SSRIs: observe for increased serotonin syndrome risk.